Compare NOA & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NOA | PBYI |
|---|---|---|
| Founded | 1953 | 2010 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Meat/Poultry/Fish | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 349.9M | 413.3M |
| IPO Year | 2006 | 2011 |
| Metric | NOA | PBYI |
|---|---|---|
| Price | $13.43 | $9.27 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 56.1K | ★ 286.1K |
| Earning Date | 05-13-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.40% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.08 |
| Revenue | N/A | ★ $27,685,000.00 |
| Revenue This Year | $14.77 | N/A |
| Revenue Next Year | $5.43 | N/A |
| P/E Ratio | ★ $18.05 | $114.00 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.07 | $4.30 |
| 52 Week High | $17.26 | $9.51 |
| Indicator | NOA | PBYI |
|---|---|---|
| Relative Strength Index (RSI) | 43.79 | 62.07 |
| Support Level | $12.97 | $7.44 |
| Resistance Level | $14.51 | $9.40 |
| Average True Range (ATR) | 0.55 | 0.42 |
| MACD | -0.12 | 0.04 |
| Stochastic Oscillator | 3.68 | 82.42 |
North American Construction Group Ltd is Canada's heavy civil construction and mining contractor provider. The company has provided services to oil, natural gas, and resource companies. The Company provides a wide range of mining and heavy civil construction services to customer in the resource development and industrial construction sectors within Canada, the United States, and Australia. The Company's reportable segments are Heavy Equipment Canada, Heavy Equipment Australia, and Other. Heavy Equipment Canada and Heavy Equipment Australia include all of aspects of the mining and heavy civil construction services provided within those geographic areas. Other includes mine management contract work in the United States, its external maintenance and rebuild programs.
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also, it is developing Alisertib, a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis, resulting in apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.